Home › Funds › Vestal Point Capital, LP › CBIO
Vestal Point Capital, LP position in CBIO
CRESCENT BIOPHARMA INC. · Health Care
Vestal Point Capital, LP reported holding 3,000,000 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q3 2026 13F filing — a position valued at US$43.8M, representing 1.13% of its reported portfolio and ranking #18 among its reported holdings. Vestal Point Capital, LP has disclosed CBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's CBIO position evolved
Vestal Point Capital, LP first disclosed a stake in CBIO in Q4 2025 at 1,500,000 shares (US$17.8M). The position peaked in Q3 2026 at 3,000,000 shares, worth US$43.8M. Across 4 filings, Vestal Point Capital, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 3,000,000 shares valued at US$43.8M — an increase of 1,370,000 shares quarter over quarter.. Notable position changes include a 84% increase in Q3 2026 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.50M | $17.79M | New |
| Q1 2026 | 1.50M | $27.55M | Hold |
| Q2 2026 | 1.63M | $29.34M | Add |
| Q3 2026 | 3.00M | $43.77M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CBIO and 13F data
CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 66 other funds we track also report a position in CBIO — the largest reported positions include Fairmount Funds Management LLC (US$52.5M), BVF INC/IL (US$45.1M), Venrock Adviser, LLC (US$31.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CBIO
- Fairmount Funds Management LLC 3.60M sh · $52.54M · Q3 2026
- BVF INC/IL 3.09M sh · $45.14M · Q3 2026
- Venrock Adviser, LLC 2.13M sh · $31.13M · Q3 2026
- FCPM III SERVICES B.V. 2.02M sh · $29.51M · Q3 2026
- Opaleye Management Inc. 1.32M sh · $23.75M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.16M sh · $16.92M · Q3 2026
- Logos Global Management LP 850.00K sh · $12.40M · Q3 2026
- NEXTBio Capital Management LP 372.86K sh · $5.44M · Q3 2026
- Remedium Capital Partners, LLC 361.25K sh · $5.27M · Q3 2026
- Squadron Capital Management LLC 350.00K sh · $5.11M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 279.72K sh · $4.08M · Q3 2026
- Boxer Capital Management, LLC 226.84K sh · $3.31M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held CBIO?
Vestal Point Capital, LP has disclosed CBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Vestal Point Capital, LP's current position in CBIO?
As of Q3 2026, Vestal Point Capital, LP holds 3.00M shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $43.77M, representing 1.13% of its reported portfolio and ranking #18.
Has Vestal Point Capital, LP been buying or selling CBIO?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP increased its position in CBIO. The position peaked in Q3 2026 at 3.00M shares.
Which other funds hold CBIO?
Other major institutional holders of CBIO include Fairmount Funds Management LLC, BVF INC/IL, Venrock Adviser, LLC, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.